BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:REGN5837 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of REGN5837\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05685173-11304@assetmemo.bio
DTSTAMP:20261121T004536Z
DTSTART;VALUE=DATE:20290216
DTEND;VALUE=DATE:20290217
SUMMARY:REGN5837: Phase 1 readout est. (NCT05685173)
DESCRIPTION:REGN5837\, phase 1\, B-Cell Non-Hodgkin Lymphoma.\nStudy: A Tri
 al to Study if REGN5837 in Combination With Odronextamab is Safe for Adult
  Participants With Aggressive B-cell Non-Hodgkin Lymphomas\nEstimated prim
 ary completion: 16 February 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/regn5837#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05685173
URL:https://assetmemo.bio/drug/regn5837#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
